IGC Pharma’s Board of Directors has approved a shift in the company’s fiscal year end from March 31 to December 31, effective December 31, 2025. This change brings IGC’s reporting cycle in line with standard U.S. public company practice and enhances comparability with peer data. CEO Ram Mukunda emphasized that the alignment will facilitate more timely financial disclosures, streamline audit processes, and improve engagement with institutional investors and analysts. The new December 31 year end is expected to reduce complexity in quarterly guidance and simplify U.S. Securities and Exchange Commission reporting requirements.

On January 5, 2026, IGC Pharma entered into a Subscription Agreement for a registered direct offering of 779,997 common shares to a group of institutional and accredited investors. The transaction is expected to generate gross proceeds of approximately $234,000, before offering expenses. Net proceeds will be deployed to support the ongoing IGC-AD1 Phase 2 clinical trial in mild to moderate Alzheimer’s disease, including patient enrollment, biomarker assays, data analysis, and regulatory interactions. Management indicated that this disciplined capital raise aligns with the company’s objective of extending its cash runway through key Phase 2 readouts and value‐creation milestones.